US panel rejects breast cancer indication for J&J's Doxil
16 July 2009
Sue Sutter
The US
FDA's oncologic drugs advisory committee has unanimously recommended against adding a breast cancer indication to
Centocor Ortho Biotech's (
Johnson & Johnson) anthracycline chemotherapeutic Doxil (pegylated liposomal doxorubicin). The committee said that the addition of Doxil...
Please Login to read the full article.